What To Know
- “We believe this is a unique way for migraine headache patients to try a great device in a convenient, affordable way through a telemedicine visit on the UpScript platform.
- “At UpScript, we are pleased to be providing US patients the opportunity to try Nerivio, a unique prescribed therapeutics device which is now available for reimbursement,” added UpScript CEO Peter Ax.
April 12, 2021
Nerivio (FDA-authorized) prescribed wearable for the acute treatment of migraine is now eligible for insurance coverage through the UpScript direct-to-patient telemedicine platform.
“It is our mission to make Nerivio accessible to everyone who experiences migraine episodes,” said Theranica CEO Alon Ironi. “We appreciate the efforts UpScript made to make Nerivio available and covered through its advanced telemedicine platform.
People with migraine need rapid, affordable access to safe and effective therapies, and this is exactly what they can get using UpScript. This service connects any patient with a trained healthcare provider and, if they secure a prescription, a quick path to receiving their device, anywhere in the United States.”
Nerivio’s list price (Wholesale Acquisition Price, or WAC) is $599 for a 12-treatment unit. The Nerivio Patient Savings Program and reimbursement hub implementation enables Theranica to offer eligible patients with health insurance a co-pay as low as $10, depending on specific plan coverage. Nerivio is also covered by United States Veterans Administration (VA) system health insurance.
“At UpScript, we are pleased to be providing US patients the opportunity to try Nerivio, a unique prescribed therapeutics device which is now available for reimbursement,” added UpScript CEO Peter Ax. “We believe this is a unique way for migraine headache patients to try a great device in a convenient, affordable way through a telemedicine visit on the UpScript platform.”
